BDTX vs. XERS, MAZE, TECX, MGTX, MLYS, TRDA, RNAC, HUMA, ARCT, and SNDL
Should you be buying Black Diamond Therapeutics stock or one of its competitors? The main competitors of Black Diamond Therapeutics include Xeris Biopharma (XERS), Maze Therapeutics (MAZE), Tectonic Therapeutic (TECX), MeiraGTx (MGTX), Mineralys Therapeutics (MLYS), Entrada Therapeutics (TRDA), Cartesian Therapeutics (RNAC), Humacyte (HUMA), Arcturus Therapeutics (ARCT), and SNDL (SNDL). These companies are all part of the "pharmaceutical products" industry.
Black Diamond Therapeutics vs.
Black Diamond Therapeutics (NASDAQ:BDTX) and Xeris Biopharma (NASDAQ:XERS) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, valuation, dividends, media sentiment, institutional ownership, profitability, community ranking, earnings and risk.
Xeris Biopharma received 93 more outperform votes than Black Diamond Therapeutics when rated by MarketBeat users. Likewise, 69.90% of users gave Xeris Biopharma an outperform vote while only 69.86% of users gave Black Diamond Therapeutics an outperform vote.
Black Diamond Therapeutics currently has a consensus target price of $15.50, indicating a potential upside of 617.59%. Xeris Biopharma has a consensus target price of $5.15, indicating a potential upside of 37.33%. Given Black Diamond Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Black Diamond Therapeutics is more favorable than Xeris Biopharma.
Black Diamond Therapeutics has a beta of 2.51, suggesting that its stock price is 151% more volatile than the S&P 500. Comparatively, Xeris Biopharma has a beta of 2.61, suggesting that its stock price is 161% more volatile than the S&P 500.
In the previous week, Black Diamond Therapeutics and Black Diamond Therapeutics both had 2 articles in the media. Black Diamond Therapeutics' average media sentiment score of 1.46 beat Xeris Biopharma's score of 0.65 indicating that Black Diamond Therapeutics is being referred to more favorably in the media.
95.5% of Black Diamond Therapeutics shares are owned by institutional investors. Comparatively, 42.8% of Xeris Biopharma shares are owned by institutional investors. 8.9% of Black Diamond Therapeutics shares are owned by insiders. Comparatively, 4.6% of Xeris Biopharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Black Diamond Therapeutics has a net margin of 0.00% compared to Xeris Biopharma's net margin of -33.69%. Xeris Biopharma's return on equity of 0.00% beat Black Diamond Therapeutics' return on equity.
Xeris Biopharma has higher revenue and earnings than Black Diamond Therapeutics. Xeris Biopharma is trading at a lower price-to-earnings ratio than Black Diamond Therapeutics, indicating that it is currently the more affordable of the two stocks.
Summary
Black Diamond Therapeutics and Xeris Biopharma tied by winning 8 of the 16 factors compared between the two stocks.
Get Black Diamond Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for BDTX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Black Diamond Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:BDTX) was last updated on 2/22/2025 by MarketBeat.com Staff
Free BDTX Stock Alerts